Issue Date | Title | Involved Person(s) |
20-Jun-2022 | Cost-effectiveness, burden of disease and budget impact of inclisiran : dynamic cohort modelling of a real-world population with cardiovascular disease | Galactionova, Katya; Salari, Paola; Mattli, Renato; Rachamin, Yael; Meier, Rahel, et al |
6-Jan-2022 | Was bringen Demenzmedikamente der Gesellschaft? | Mattli, Renato |
2022 | The value of prevention : a health economics perspective | Marti, Joachim; Mattli, Renato; Nicolet, Anna; Wieser, Simon |
2022 | Health technology assessment (HTA) : medicines for dementia due to Alzheimer's and Parkinson's disease | Mattli, R.; Tomonaga, Y.; Tzogiou, C.; Vinci, L.; Sharakin, M., et al |
2022 | Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis | Mattli, Renato; Grobet, Cécile; Sharakin, Maxim; Pöhlmann, Johannes; Vinci, Linda, et al |